Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumours

References

• Oberg K, Knigge U, Kwekkeboom D, ESMO Guidelines Working Group, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii124–130.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, WHO Classification of Tumours Editorial Board, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188.
   PubMed Web of Science ®Google Scholar
• Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351(9100):417–418.
   PubMed Web of Science ®Google Scholar
• Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–731.
   PubMedGoogle Scholar
• Severi S, Grassi I, Nicolini S, et al. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Onco Targets Ther. 2017;10:551–557.
   PubMed Web of Science ®Google Scholar
• Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–2423.
   PubMed Web of Science ®Google Scholar
• Bushnell DL, Jr., O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652–1659.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity. J Clin Oncol. 2008;26(13):2124–2130.
   PubMed Web of Science ®Google Scholar
• Sward C, Bernhardt P, Ahlman H, et al. [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J Surg. 2010;34(6):1368–721372.
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–2135.
   PubMed Web of Science ®Google Scholar
• Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46(Suppl 1):83s–891s.
   PubMed Web of Science ®Google Scholar
• Rolleman EJ, Melis M, Valkema R, et al. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2010;37(5):1018–1031.
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847–1856.
   PubMed Web of Science ®Google Scholar
• Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439–1447.
   PubMedGoogle Scholar
• Groth S, Aasted M. 51Cr-EDTA clearance determined by one plasma sample. Clin Physiol. 1981;1(4):417–425.
   PubMedGoogle Scholar
• Genovese F, Manresa AA, Leeming DJ, et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair. 2014;7(1):4.
   PubMedGoogle Scholar
• Leeming DJ, Byrjalsen I, Jimenez W, et al. Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis—a serological evaluation. Liver Int. 2013;33(3):439–447.
   PubMed Web of Science ®Google Scholar
• Veidal SS, Karsdal MA, Vassiliadis E, et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis—identification and validation of a novel biochemical marker assay. PLoS One. 2011;6(9):e24753.
   PubMed Web of Science ®Google Scholar
• Veidal SS, Vassiliadis E, Barascuk N, et al. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int. 2010;30(9):1293–1304.
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Sand JM, Nielsen MJ, et al. Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark Insights. 2012;7:119–126.
   PubMedGoogle Scholar
• Papasotiriou M, Genovese F, Klinkhammer BM, et al. Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases. Nephrol Dial Transplant. 2015;30(7):1112–1121.
   PubMed Web of Science ®Google Scholar
• Hijmans RS, Rasmussen DG, Yazdani S, et al. Urinary collagen degradation products as early markers of progressive renal fibrosis. J Transl Med. 2017;15(1):63.
   PubMedGoogle Scholar
• Genovese F, Boor P, Papasotiriou M, et al. Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy. Nephrol Dial Transplant. 2016;31(3):472–479.
   PubMed Web of Science ®Google Scholar
• Stribos EGD, Nielsen SH, Brix S, et al. Non-invasive quantification of collagen turnover in renal transplant recipients. PLoS One. 2017;12(4):e0175898.
   PubMed Web of Science ®Google Scholar
• Rasmussen DGK, Hansen TW, von Scholten BJ, et al. Higher collagen VI formation is associated with all-cause mortality in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2018;41(7):1493–1500.
   PubMed Web of Science ®Google Scholar
• Rasmussen DGK, Boesby L, Nielsen SH, et al. Collagen turnover profiles in chronic kidney disease. Sci Rep. 2019;9(1):16062.
   PubMedGoogle Scholar
• Yepes-Calderón M, Sotomayor CG, Rasmussen DGK, et al. Biopsy-controlled non-invasive quantification of collagen type vi in kidney transplant recipients: a post-hoc analysis of the MECANO trial. J Clin Med. 2020;9:3216
   PubMed Web of Science ®Google Scholar
• Barascuk N, Veidal SS, Larsen L, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43(10-11):899–904.
   PubMed Web of Science ®Google Scholar
• Sun S, Henriksen K, Karsdal MA, et al. Collagen type III and VI turnover in response to long-term immobilization. PLoS One. 2015;10(12):e0144525.
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5:303–315.
   PubMed Web of Science ®Google Scholar
• Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684–696.
   PubMed Web of Science ®Google Scholar
• Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010;6(11):643–656.
   PubMed Web of Science ®Google Scholar
• Erbas B, Tuncel M. Renal function assessment during peptide receptor radionuclide therapy. Semin Nucl Med. 2016;46(5):462–478.
   PubMed Web of Science ®Google Scholar
• Genovese F, Rasmussen DGK, Karsdal MA, et al. Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients. Clin Kidney J. 2021;14(2):593–601.
   PubMed Web of Science ®Google Scholar
• Costigan M, Chambers DA, Boot-Handford RP. Collagen turnover in renal disease. Exp Nephrol. 1995;3(2):114–121.
   PubMedGoogle Scholar
• Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Annu Rev Biochem. 1984;53:717–748.
   PubMed Web of Science ®Google Scholar
• Reiser K, McCormick RJ, Rucker RB. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J. 1992;6(7):2439–2449.
   PubMed Web of Science ®Google Scholar
• van der Slot-Verhoeven AJ, van Dura EA, Attema J, et al. The type of collagen cross-link determines the reversibility of experimental skin fibrosis. Biochim Biophys Acta. 2005;1740(1):60–67.
   PubMed Web of Science ®Google Scholar
• Arveschoug AK, Kramer SM, Iversen P, et al. Monitoring kidney function in neuroendocrine tumor patients treated with (90)Y-DOTATOC: associations with risk factors. Curr Radiopharm. 2015;8(1):49–55.
   PubMed Web of Science ®Google Scholar